English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme of many presentations by Fred Hutch Cancer Center experts, including: Meta-analyses show socioeconomic factors limit access to transplants and clinical trials, highlighting strategies to overcome barriers.
Tag: Hematologic Cancers
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip Sheet
Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami will be presented at the Annual Meeting & Exposition of the American Society of Hematology in San Diego, Dec. 7-10.
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from The University of Texas MD Anderson Cancer Center.
Non-Hodgkin lymphoma mortality disparities across different sexes, races, and geographic locations
Background: Non-Hodgkin lymphoma (NHL) is one of the common hematological cancers in the United States (U.S.), accounting for 4% of new cancer cases in 2023. The mortality rate of NHL is the sixth highest among all cancers in the U.S. Our…
Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
National Comprehensive Cancer Network Announces Collaboration with Blood Cancer Experts in Poland
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
Tulane expert lauds new ‘cutting edge’ hemophilia treatment
A new treatment that helps people with hemophilia A maintain higher levels of a crucial blood clotting factor with fewer treatments is a victory for patients, according to a new editorial in The New England Journal of Medicine this week by Dr. Cindy…
NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
KU Cancer Center researchers discover that people with blood-related cancers have a higher chance of COVID breakthrough infections
Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.
There’s a Better Way to Detect High-Risk Medications in Older Adults with Cancer According to New Study in JNCCN
Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.
Utah Researchers Illuminate Potential Precursors of Blood Cancers
Utah researchers report significant new insights into the development of blood cancers. Comparing DNA data in people with and without blood disorders, the researchers discovered genetic mutations in about 2% of the presumably healthy participants that were identical to those frequently observed in the cancer patients. These findings provide new clues about mutations that may initiate cancer development and those that may help cancer progress.
New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
NCCN Meeting on Blood Cancers Will Be Virtual for the First Time
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.